Disorders of the Liver Excluding Hepatitis A, B, C, D, and E

Part of the Clinical Gastroenterology book series (CG)


Liver disease is one of the most common non-AIDS-related causes of death in HIV-infected patients, but the incidence may be declining with advances in antiretroviral therapy (Jennifer and Thio, Clin Gastroenterol Hepatol 8:1002–1012, 2010; Pettit et al. J Int AIDS Soc 21, 2018; Sherman et al. Hepatology 62:1871–1882, 2015). Recognizing and treating opportunistic infections of the liver is essential in the care of HIV-infected patients. This chapter will review the epidemiology, pathophysiology, and clinical presentation along with diagnostic testing and treatment of the most common hepatic presentations of HIV opportunistic fungal, bacterial, viral, and mycobacterial diseases. This chapter will emphasize the less common and often non-hepatotropic viral infections. The more common viral hepatitides, hepatitis A, B, C, D, and E, will be discussed in greater detail in another chapter. In addition to infectious processes that can cause hepatic injury, treatment of HIV with HAART and other medications used for the treatment and prevention of opportunistic infections can lead to drug-induced liver injury (DILI). Since liver injury has a broad differential and can mimic vascular and neoplastic diseases, it takes an astute physician to recognize opportunistic infections and DILI that occur in HIV-infected persons. Clinicians must be aware of these potentially serious hepatic effects when managing HIV-positive patients.


Human immunodeficiency virus (HIV) Opportunistic infections Antiretroviral therapy (ART) Drug-induced liver injury (DILI) Hepatitis Liver failure 


  1. 1.
    Jennifer JC, Thio CL. Liver disease in the HIV–infected individual. Clin Gastroenterol Hepatol. 2010;8:1002–12.CrossRefGoogle Scholar
  2. 2.
    Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, et al. Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. J Int AIDS Soc. 2018;21. Scholar
  3. 3.
    Sherman KE, Rockstroh J, Thomas D. HIV and liver disease: an update. Hepatology. 2015;62:1871–82.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI. Revised surveillance case definition for HIV infection — United States, 2014. Morb Mortal Wkly Rep Recomm Rep. 2014;63:1–10.Google Scholar
  5. 5.
    Alcabes P, Munoz A, Vlahov D, Friedland GH. Incubation period of human immunodeficiency virus. Epidemiol Rev. 1993;15:303–18.PubMedCrossRefGoogle Scholar
  6. 6.
    Bacchetti P, Moss AR. Incubation period of AIDS in San Francisco. Nature. 1989;338:251–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Darling ST. A protozoon general infection producing pseudotubercles in the lungs and focal necroses in the liver, spleen and lymphnodes. J Am Med Assoc. 1906;46:1283–5.CrossRefGoogle Scholar
  8. 8.
    Deepee GS. In: Bennett JE, Dolin R, Blaser MJ, editors. Histoplasma capsulatum (Histoplasmosis). Philadelphia: Saunders; 2015. p. 2949–62.Google Scholar
  9. 9.
    da Rocha-Lima H. Histoplasmose und epizootische lymphangitis. Arch Schiffs Tropenhyg. 1912;16:79.Google Scholar
  10. 10.
    Benedict K, Mody RK. Epidemiology of histoplasmosis outbreaks, United States, 1938–2013. Emerg Infect Dis. 2016;22:370–8.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Adenis A, Aznar C, Couppie P. Histoplasmosis in HIV-infected patients: a review of new developments and remaining gaps. Curr Trop Med Rep. 2014;1:119–28.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Huber F, Nacher M, Aznar C, Pierre-Demar M, El Guedj M, Vaz T, et al. AIDS-related histoplasma capsulatum var. capsulatum infection: 25 years experience of French Guiana. AIDS. 2008;22:1047–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Colombo AL, Tobon A, Restrepo A, Queiroz-Telles F, Nucci M. Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol. 2011;49:785–98.PubMedGoogle Scholar
  14. 14.
    Cruz R. Histoplasma capsulatum var. capsulatum Darling. Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia. 2013;30:311.CrossRefGoogle Scholar
  15. 15.
    Garsaud P, Boisseau-Garsaud A-M, Desbois N, Verneuil L, Cales-Quist D, Helenon R, et al. Epidemiology of histoplasmosis in the French West Indies (Martinique). Trans R Soc Trop Med Hyg. 1999;93:264–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Fernandez Andreu CM, Martinez MG. The sources of histoplasmosis infection on the Isla de la Juventud. Cuba Revista do Instituto de Medicina Tropical de Sao Paulo. 1992;34:441.PubMedCrossRefGoogle Scholar
  17. 17.
    Pan B, Chen M, Pan W, Liao W. Histoplasmosis: a new endemic fungal infection in China? Review and analysis of cases. Mycoses. 2013;56:212–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Gopalakrishnan R, Nambi PS, Ramasubramanian V, Abdul Ghafur K, Parameswaran A. Histoplasmosis in India: truly uncommon or uncommonly recognised? J Assoc Physicians India. 2012;60:25–8.PubMedGoogle Scholar
  19. 19.
    Bulmer A, Bulmer G. Incidence of histoplasmin hypersensitivity in the Philippines. Mycopathologia. 2001;149:69–71.PubMedCrossRefGoogle Scholar
  20. 20.
    Chakrabarti A, Slavin MA. Endemic fungal infections in the Asia-Pacific region. Med Mycol. 2011;49:337–44.PubMedCrossRefGoogle Scholar
  21. 21.
    McLeod DSA, Perry-Keene DA, Allworth A, Perry-Keene J, Coulter C, Robson JMB, et al. Histoplasmosis in Australia: report of 16 cases and literature review. Medicine. 2011;90:61.PubMedCrossRefGoogle Scholar
  22. 22.
    Bajwa S, Kulshrestha A. Fungal infections in intensive care unit: challenges in diagnosis and management. Ann Med Health Sci Res. 2013;3:238–44.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Miller R, Assi M. Endemic fungal infections in solid organ transplantation. Am J Transplant. 2013;13:250–61.PubMedCrossRefGoogle Scholar
  24. 24.
    Wheat J. Endemic mycoses in AIDS: a clinical review. Clin Microbiol Rev. 1995;8:146–59.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Woods JP. Revisiting old friends: developments in understanding histoplasma capsulatum pathogenesis. J Microbiol. 2016;54:265–76.PubMedCrossRefGoogle Scholar
  26. 26.
    Oliver A, Ciulla T, Comer G. New and classic insights into presumed ocular histoplasmosis syndrome and its treatment. Curr Opin Ophthalmol. 2005;16:160–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Giles CL, Falls HF. Amphotericin B therapy in the treatment of presumed histoplasma chorioretinitis. A further appraisal. Am J Ophthalmol. 1968;66:101–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Newman SL, Gootee L, Brunner G, Deepe GS. Chloroquine induces human macrophage killing of histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. J Clin Invest. 1994;93:1422–9.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807–25.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Goodwin RA, Loyd JE, Des Prez RM. Histoplasmosis in normal hosts. Medicine. 1981;60:231–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Storch G, Burford JG, George RB, Kaufman L, Ajello L. Acute histoplasmosis. Description of an outbreak in northern Louisiana. Chest. 1980;77:38.PubMedCrossRefGoogle Scholar
  32. 32.
    Caceres DH, Tobon AM, Angela R, Chiller T, Gomez BL. The important role of co-infections in patients with AIDS and progressive disseminated histoplasmosis (PDH): A cohort from Colombia. Med Mycol Case Rep: Elsevier. 2018;19:41–4.CrossRefGoogle Scholar
  33. 33.
    Eidbo J, Sanchez RL, Tschen JA, Ellner KM. Cutaneous manifestations of histoplasmosis in the acquired immune deficiency syndrome. Am J Surg Pathol. 1993;17:110–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Gutierrez ME, Canton A, Sosa N, Puga E, Talavera L. Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 cases. Clin Infect Dis. 2005;40:1199–202. Oxford: University of Chicago Press.PubMedCrossRefGoogle Scholar
  35. 35.
    Pietrobon D, Negro-Marquinez L, Kilstein J, Galindez J, Greca A, Battagliotti C. Disseminated histoplasmosis and AIDS in an argentine hospital: clinical manifestations, diagnosis and treatment. Enferm Infecc Microbiol Clin. 2004;22:156.PubMedCrossRefGoogle Scholar
  36. 36.
    Corti M, Negroni R, Esquivel P, Villafane MF. Disseminated histoplasmosis in patients with AIDS: epidemiological, clinical, microbiological and immunological analysis of 26 patients. Enferm Emerg. 2004;6:8–15.Google Scholar
  37. 37.
    Torales M, Cardozo A, Savio E. Disseminated histoplasmosis in HIV positive patients: seven years of experience [in Spanish]. In: Program and abstracts of the XIth Panamerican Congress of Infectious Diseases (Cordoba, Argentina). 2003.Google Scholar
  38. 38.
    Wheat LJ, Batteiger BE, Sathapatayavongs B. Histoplasma capsulatum infections of the central nervous system A clinical review. Medicine. 1990;69:244.PubMedCrossRefGoogle Scholar
  39. 39.
    Goswami R, Pramanik N, Banerjee D, Raza M, Guha S, Maiti P. Histoplasmosis in eastern India: the tip of the iceberg? Trans R Soc Trop Med Hyg. 1999;93:540–2.PubMedCrossRefGoogle Scholar
  40. 40.
    Burke DG, Emancipator SN, Smith MC, Salata RA. Histoplasmosis and kidney disease in patients with AIDS. Clin Infect Dis. 1997;25:281–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Butt AA, Michaels S, Greer D, Clark R, Kissinger P, Martin DH. Serum LDH level as a clue to the diagnosis of histoplasmosis. AIDS Read. 2002;12:317.PubMedGoogle Scholar
  42. 42.
    Corcoran GR, Al-Abdely H, Flanders CD, Geimer J, Patterson TF. Markedly elevated serum lactate dehydrogenase levels are a clue to the diagnosis of disseminated histoplasmosis in patients with AIDS. Clin Infect Dis. 1997;24:942–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Hage C, Azar M, Bahr N, Loyd J, Wheat L. Histoplasmosis: up-to-date evidence-based approach to diagnosis and management. Semin Respir Crit Care Med. 2015;36:729–45.PubMedCrossRefGoogle Scholar
  44. 44.
    Azar M, Hage C. Laboratory diagnostics for histoplasmosis. J Clin Microbiol. 2017;55:1612–20.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Gupta N, Arora SK, Rajwanshi A, Nijhawan R, Srinivasan R. Histoplasmosis: cytodiagnosis and review of literature with special emphasis on differential diagnosis on cytomorphology. Cytopathology : Official Journal of the British Society for Clinical Cytology. 2010;21:240.CrossRefGoogle Scholar
  46. 46.
    Coash M, Forouhar F, Wu GY. Granulomatous liver diseases: a review. J Formos Med Assoc. 2012;111:3–13.PubMedCrossRefGoogle Scholar
  47. 47.
    Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis. 2011;53:448–54.PubMedCrossRefGoogle Scholar
  48. 48.
    Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev, United States: American Society for Microbiology. 2007;20:115–32.CrossRefGoogle Scholar
  49. 49.
    Hage CA, Davis TE, Fuller D, Egan L, Witt JR, Wheat LJ, et al. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest. 2010;36:623–8.CrossRefGoogle Scholar
  50. 50.
    Wheat LJ, Azar MM, Bahr NC, Spec A, Relich RF, Hage C. Histoplasmosis. Infect Dis Clin N Am. 2010;137:623–8.Google Scholar
  51. 51.
    Babady NE, Buckwalter SP, Hall L, Febre KML, Binnicker MJ, Wengenack NL. Detection of blastomyces dermatitidis and histoplasma capsulatum from culture isolates and clinical specimens by use of real-time PCR. J Clin Microbiol. 2011;49:3204–8.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Wingard JR, Leather H. Hepatotoxicity associated with antifungal therapy after bone marrow transplantation. Clin Infect Dis. 2005;41:308–10.PubMedCrossRefGoogle Scholar
  54. 54.
    Ellis M, Shamoon A, Gorka W, Zwaan F, al-Ramadi B. Severe hepatic injury associated with lipid formulations of amphotericin B. Clin Infect Dis. 2001;32:e87–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Petit N, Parola P, Dhiver C, Gastaut J-A. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients. J Antimicrob Chemother. 1996;38:154–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Lou H-Y, Fang C-L, Fang S-U, Tiong C, Cheng Y-C, Chang C-C. Hepatic failure related to itraconazole use successfully treated by corticosteroids. Hepat Mon. 2011;11:843–6.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis. 1999;28:1049–56.PubMedCrossRefGoogle Scholar
  58. 58.
    Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: what do we know now. Fungal Genet Biol. 2015;78:49–54.PubMedCrossRefGoogle Scholar
  59. 59.
    Shaheen AA, Somayaji R, Myers R, Mody CH. Epidemiology and trends of cryptococcosis in the United States from 2000 to 2007: A population-based study. Int J STD AIDS. 2018;29:453–60.PubMedCrossRefGoogle Scholar
  60. 60.
    Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2000;30:710–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr. 1991;4:770.PubMedGoogle Scholar
  62. 62.
    Perfect J. Cryptococcosis (Cryptococcus neoformans and Cryptococcus gattii). In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia: Elsevier, Saunders; 2015. p. 2934–48.Google Scholar
  63. 63.
    Casadevall A, Perfect JR. The history of Cryptococcus and Cryptococcosis. In: Anonymous Cryptococcus. Washington DC: ASM Press; 2011. p. 17–26.Google Scholar
  64. 64.
    Sabesin SM, Fallon HJ, Andriole VT. Hepatic failure as a manifestation of Cryptococcosis. Arch Intern Med. 1963;111:661–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Joshi MD, Gathua SN, Okelo GB, Lule GN, Musewe AO. Cryptococcal hepatitis and meningitis in a patient with acquired immunodeficiency syndrome: a case report. East Afr Med J. 1989;66:69.PubMedGoogle Scholar
  66. 66.
    Lefton HB, Farmer RG, Buchwald R, Haselby R. Cryptococcal hepatitis mimicking primary sclerosing cholangitis. Gastroenterology. 1974;67:511.PubMedCrossRefGoogle Scholar
  67. 67.
    Gollan JL, Davidson GP, Anderson K, White TA, Kimber CL. Visceral cryptococcosis without central nervous system or pulmonary involvement: presentation as hepatitis. Med J Aust. 1972;1:469.PubMedGoogle Scholar
  68. 68.
    Wright L, Bubb W, Davidson J, Santangelo R, Krockenberger M, Himmelreich U, et al. Metabolites released by Cryptococcus neoformans var. neoformans and var. gattii differentially affect human neutrophil function. Microbes Infect. 2002;4:1427–38.PubMedCrossRefGoogle Scholar
  69. 69.
    Procknow JJ. Cryptococcal hepatitis presenting as a surgical emergency. First isolation of Cryptococcus neoformans from point source in Chicago. JAMA. 1965;191:269–74.PubMedCrossRefGoogle Scholar
  70. 70.
    Goenka MK, Mehta S, Yachha SK, Nagi B, Chakraborty A, Malik AK. Hepatic involvement culminating in cirrhosis in a child with disseminated Cryptococcosis. J Clin Gastroenterol. 1995;20:57–60.PubMedCrossRefGoogle Scholar
  71. 71.
    Levitz SM. Cryptococcus neoformans by Casadevall, Arturo; Perfect, John R. Med Mycol. 1999;37:371.CrossRefGoogle Scholar
  72. 72.
    Schwartz DA. Characterization of the biological activity of Cryptococcus infections in surgical pathology. The Budding Index and Carminophilic Index. Ann Clin Lab Sci. 1988;18:388.PubMedGoogle Scholar
  73. 73.
    Lee SC, Dickson DW, Casadevall A. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol. 1996;27:839–47.PubMedCrossRefGoogle Scholar
  74. 74.
    Singh N, Husain S, De Vera M, Gayowski T, Cacciarelli TV. Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine. 2004;83:188–92.PubMedCrossRefGoogle Scholar
  75. 75.
    Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the Management of Cryptococcal Disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Jacobson MA, Hanks DK, Ferrell LD. Fatal acute hepatic necrosis due to fluconazole. Am J Med. 1994;96:188–90.PubMedCrossRefGoogle Scholar
  77. 77.
    Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, et al. Discontinuation of secondary prophylaxis for Cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: A prospective, multicenter, randomized study. Clin Infect Dis. 2003;36:1329–31.PubMedCrossRefGoogle Scholar
  78. 78.
    Zolopa AR, Andersen J, Komarow L, Sanne I, Sanchez A, Hogg E, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLoS One. 2009;4:e5575.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Milefchik E, Ann Leal M, Haubrich R, Bozzette SA, Tilles JG, Leedom JM, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol. 2008;46:393–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Eulalio K, de Macedo R, Salmito Cavalcanti M, Soares Martins L, Lazera M, Wanke B. Coccidioides immitis isolated from armadillos (Dasypus novemcinctus) in the state of Piauí, Northeast Brazil. Mycopathologia. 2001;149:57–61.PubMedCrossRefGoogle Scholar
  81. 81.
    Posada A. Un nuevo caso de micosis fungoidea con psorospermias. An Circ Med Argent. 1892;15:585–97.Google Scholar
  82. 82.
    Galgiani JN. Coccidioidomycosis (Coccidioides Species). In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia: Elsevier, Saunders; 2015. p. 2974–84.Google Scholar
  83. 83.
    Ramani R, Chaturvedi V. Antifungal susceptibility profiles of Coccidioides immitis and Coccidioides posadasii from endemic and non-endemic areas. Mycopathologia. 2007;163:315–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Tsang CA, Tabnak F, Vugia DJ, Benedict K, Chiller T, Park BJ. Increase in reported coccidioidomycosis — United States, 1998–2011. Morb Mortal Wkly Rep. 2013;62:217–21.Google Scholar
  85. 85.
    Huang JY, Bristow B, Shafir S, Sorvillo F. Coccidioidomycosis-associated deaths, United States, 1990–2008. Emerg Infect Dis. 2012;18:1723.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Hernandez J, Echevarria S, Garcia-Valtuille A, Mazorra F, Salesa R. Atypical coccidioidomycosis in an AIDS patient successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis. 1997;16:592–4.PubMedCrossRefGoogle Scholar
  87. 87.
    Howard PF. Diagnosis of disseminated coccidioidomycosis by liver biopsy. Arch Intern Med. 1983;143:1335–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Kokseng S, Blair J. Subclinical dissemination of coccidioidomycosis in a liver transplant recipient. Mycopathologia. 2011;172:223–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Smith CE, Beard RR. Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases. Am J Public Health Nations Health. 1946;36:1394–402.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Louie L, Ng S, Hajjeh R, Johnson R, Vugia D, Werner SB, et al. Influence of host genetics on the severity of coccidioidomycosis. Emerg Infect Dis. 1999;5:672.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Deresinski SC, Pappagianis D, Stevens DA. Association of abo blood group and outcome of coccidioidal infection. Med Mycol. 1979;17:261–4.CrossRefGoogle Scholar
  92. 92.
    Crum NF, Lederman ER, Stafford CM, Parrish JS, Wallace MR. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine. 2004;83:149–75.PubMedCrossRefGoogle Scholar
  93. 93.
    Valdivia L, Nix D, Wright M, Lindberg E, Fagan T, Lieberman D, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis. 2006;12:958–62.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Kuprian M, Schofield C, Bennett S. Symptomatic hepatitis secondary to disseminated coccidioidomycosis in an immunocompetent patient. BMJ Case Rep. 2014;2014:pii: bcr2013202144.CrossRefGoogle Scholar
  95. 95.
    Craig JR, Hillberg RH, Balchum OJ. Disseminated coccidioidomycosis. Diagnosis by needle biopsy of liver. West J Med. 1975;122:171–4.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Smith G, Hoover S, Klotz SA, Sobonya R. Abdominal and pelvic coccidioidomycosis. Am J Med Sci. 2011;341:308–11.PubMedCrossRefGoogle Scholar
  97. 97.
    Mendoza N, Blair JE. The utility of diagnostic testing for active coccidioidomycosis in solid organ transplant recipients. Am J Transplant. 2013;13:1034–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:1308–11.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Harley WB, Blaser MJ. Disseminated coccidioidomycosis associated with extreme eosinophilia. Clin Infect Dis. 1994;18:627–9.PubMedCrossRefGoogle Scholar
  100. 100.
    McGahan JP, Graves DS, Palmer PE, Stadalnik RC, Dublin AB. Classic and contemporary imaging of coccidioidomycosis. Am J Roentgenol. 1981;136:393.CrossRefGoogle Scholar
  101. 101.
    Adam RD, Elliott SP, Taljanovic MS. The spectrum and presentation of disseminated coccidioidomycosis. Am J Med. 2009;122:770–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Gupta NA, Iv M, Pandit RP, Patel MR. Imaging manifestations of primary and disseminated coccidioidomycosis. Appl Radiol. 2015;44:9.Google Scholar
  103. 103.
    Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, et al. Coccidioidomycosis. Clin Infect Dis. 2005;41:1217–23.PubMedCrossRefGoogle Scholar
  104. 104.
    Blair JE. Coccidioidomycosis in patients who have undergone transplantation. Ann N Y Acad Sci. 2007;1111:365–76.PubMedCrossRefGoogle Scholar
  105. 105.
    Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection: a prospective study of 110 patients. Arch Intern Med. 1991;151:1567–72.PubMedCrossRefGoogle Scholar
  106. 106.
    Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984;311:354–8.PubMedCrossRefGoogle Scholar
  107. 107.
    Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36:288–305.PubMedCrossRefGoogle Scholar
  108. 108.
    Jagadha V, Andavolu RH, Huang CT. Granulomatous inflammation in the acquired immune deficiency syndrome. Am J Clin Pathol. 1985;84:598–602.PubMedCrossRefGoogle Scholar
  109. 109.
    Poles MA, Lew EA, Dieterich DT. Diagnosis and treatment of hepatic disease in patients with HIV. Gastroenterol Clin N Am. 1997;26:291–321.CrossRefGoogle Scholar
  110. 110.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:E1.PubMedCrossRefGoogle Scholar
  111. 111.
    Cornely OA, Bangard C, Jaspers NI. Hepatosplenic candidiasis. Clin Liver Dis. 2015;6:47–50.CrossRefGoogle Scholar
  112. 112.
    Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am. 2000;14:721.PubMedCrossRefGoogle Scholar
  113. 113.
    Edwards JE. Candida species. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia: Elsevier, Saunders; 2015. p. 2879–94.Google Scholar
  114. 114.
    Cole GT, Lynn KT, Seshan KR. Evaluation of a murine model of hepatic candidiasis. J Clin Microbiol. 1990;28:1828–41.PubMedPubMedCentralGoogle Scholar
  115. 115.
    De Castro N, Mazoyer E, Porcher R, Raffoux E, Suarez F, Ribaud P, et al. Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000–2007. Clin Microbiol Infect. 2012;18:E185–7.PubMedCrossRefGoogle Scholar
  116. 116.
    Anttila V-J, Ruutu P, Bondestam S, Jansson S-E, Nordling S, Farkkila M, et al. Hepatosplenic yeast infection in patients with acute leukemia: a diagnostic problem. Clin Infect Dis. 1994;18:979–81.PubMedCrossRefGoogle Scholar
  117. 117.
    Pagano L, Mele L, Fianchi L, Melillo L, Martino B, D’Antonio D, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica. 2002;87:535.PubMedGoogle Scholar
  118. 118.
    Rammaert B, Desjardins A, Lortholary O. New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. Mycoses. 2012;55:e74–84.PubMedCrossRefGoogle Scholar
  119. 119.
    Thaler M, Pastakia B, Shwaker TH, O’Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med. 1988;108:88. United States: American College of Physicians.PubMedCrossRefGoogle Scholar
  120. 120.
    Kirby A, Chapman C, Hassan C, Burnie J. The diagnosis of hepatosplenic candidiasis by DNA analysis of tissue biopsy and serum. J Clin Pathol. 2004;57:764–5.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Masood A, Sallah S. Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. Leuk Res. 2005;29:493–501.PubMedCrossRefGoogle Scholar
  122. 122.
    Sallah S, Semelka RC, Wehbie R, Sallah W, Nguyen NP, Vos P. Hepatosplenic candidiasis in patients with acute leukaemia. Br J Haematol. 1999;106:697–701.PubMedCrossRefGoogle Scholar
  123. 123.
    Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750–70.PubMedCrossRefGoogle Scholar
  124. 124.
    Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T, et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis. 2005;51:95–101.PubMedCrossRefGoogle Scholar
  125. 125.
    Halkic N, Ksontini R. Hepatosplenic candidiasis. N Engl J Med. 2007;356:e4.PubMedCrossRefGoogle Scholar
  126. 126.
    Rudolph J, Rodenwaldt J, Ruhnke M, Hamm B, Kopka L. Unusual enhancement pattern of liver lesions in hepatosplenic candidiasis. Acta Radiol. 2004;45:499–503.PubMedCrossRefGoogle Scholar
  127. 127.
    Semelka RC, Shoenut JP, Greenberg HM, Bow EJ. Detection of acute and treated lesions of hepatosplenic candidiasis: comparison of dynamic contrast-enhanced CT and MR imaging. J Magn Reson Imaging: JMRI. 1992;2:341.PubMedCrossRefGoogle Scholar
  128. 128.
    Teyton P, Baillet G, Hindie E, Filmont J, Sarandi F, Toubert M-E, et al. Hepatosplenic candidiasis imaged with F-18 FDG PET/CT. Clin Nucl Med. 2009;34:439–40.PubMedCrossRefGoogle Scholar
  129. 129.
    Hot A, Maunoury C, Poiree S, Lanternier F, Viard J, Loulergue P, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17:409–17.PubMedCrossRefGoogle Scholar
  130. 130.
    Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med. 1991;91:137–41.PubMedCrossRefGoogle Scholar
  131. 131.
    Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med. 1991;91:142–50.PubMedCrossRefGoogle Scholar
  132. 132.
    Legrand F, Lecuit M, Dupont B, Bellaton E, Huerre M, Rohrlich P-S, et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis. 2008;46:696–702.PubMedCrossRefGoogle Scholar
  133. 133.
    Chaussade H, Bastides F, Lissandre S, Blouin P, Bailly E, Chandenier J, et al. Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review. J Antimicrob Chemother. 2012;67:1493–5.PubMedCrossRefGoogle Scholar
  134. 134.
    Cornely OA, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother. 2007;60:363–9.PubMedCrossRefGoogle Scholar
  135. 135.
    Poon LM, Chia HY, Tan LK, Liu TC, Koh LP. Successful intensive chemotherapy followed by autologous hematopoietic cell transplantation in a patient with acute myeloid leukemia and hepatosplenic candidiasis: case report and review of literature. Trans Infect Dis: An Official Journal of the Transplantation Society. 2009;11:160–6.CrossRefGoogle Scholar
  136. 136.
    Lehrnbecher T, Attarbaschi A, Duerken M, Garbino J, Gruhn B, Kontny U, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis. 2010;29:1043–5.PubMedCrossRefGoogle Scholar
  137. 137.
    Vanek J, Jirocec O. Parasitic pneumonia. Interstitial plasma cell pneumonia of premature, caused by pneumocystis Carinii. Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. 1. Abt. Medizinisch-hygienische Bakteriologie, Virusforschung und Parasitologie. Originale. 1952;158:120.PubMedGoogle Scholar
  138. 138.
    Hughes WT, Feldman S, Aur RJA, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of pneumocystis carinii pneumonitis. Cancer. 1975;36:2004–9.PubMedCrossRefGoogle Scholar
  139. 139.
    Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34:1098–107.PubMedCrossRefGoogle Scholar
  140. 140.
    Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, et al. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One. 2010;5:e8524.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Jarnum S, Rasmussen EF, Ohlsen AS, Sarensen AWS. Generalized pneumocystis carinii infection with severe idiopathic hypoproteinemia. Ann Intern Med. 1968;68:138.PubMedCrossRefGoogle Scholar
  142. 142.
    Awen CF, Baltzan MA. Systemic dissemination of pneumocystis carinii pneumonia. Can Med Assoc J. 1971;104:809.PubMedPubMedCentralGoogle Scholar
  143. 143.
    Walzer Peter D, George S, Miller RF. Pneumocystis species. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia: Elsevier, Saunders; 2015. p. 3016–30.Google Scholar
  144. 144.
    Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med. 1990;322:161–5.PubMedCrossRefGoogle Scholar
  145. 145.
    Otahbachi M, Nugent K, Buscemi D. Granulomatous pneumocystis jiroveci pneumonia in a patient with chronic lymphocytic leukemia: A literature review and hypothesis on pathogenesis. Am J Med Sci. 2007;333:131–5.PubMedCrossRefGoogle Scholar
  146. 146.
    Chew L-C, Maceda-Galang L, Tan Y, Chakraborty B, Thumboo J. Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid. JCR: J Clin Rheumatol. 2015;21:72–5.PubMedGoogle Scholar
  147. 147.
    Wei K-C, Sy C, Wu S-Y, Chuang T-J, Huang W-C, Lai P-C. Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients. Sci Rep. 2018;8:1–8.CrossRefGoogle Scholar
  148. 148.
    Rahimi SA. Disseminated pneumocystis carinii in thymic alymphoplasia. Arch Pathol. 1974;97:162.PubMedGoogle Scholar
  149. 149.
    Hagopian WA, Huseby JS. Pneumocystis hepatitis and choroiditis despite successful aerosolized pentamidine pulmonary prophylaxis. Chest. 1989;96:949–51.PubMedCrossRefGoogle Scholar
  150. 150.
    Karam MB, Mosadegh L. Extra-pulmonary pneumocystis jiroveci infection: a case report. Braz J Infect Dis. 2014;18:681–5.PubMedCrossRefGoogle Scholar
  151. 151.
    Poblete RB, Rodriguez K, Foust RT, Reddy KR, Saldana MJ. Pneumocystis carinii hepatitis in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med, United States. 1989;110:737–8.CrossRefGoogle Scholar
  152. 152.
    Pilon VA, Echols RM, Celo JS, Elmendorf SL. Disseminated pneumocystis carinii infection in AIDS. N Engl J Med. 1987;316:1410–1.PubMedCrossRefGoogle Scholar
  153. 153.
    Wilson JW, Limper AH, Grys TE, Karre T, Wengenack NL, Binnicker MJ. Pneumocystis jirovecii testing by real-time polymerase chain reaction and direct examination among immunocompetent and immunosuppressed patient groups and correlation to disease specificity. Diagn Microbiol Infect Dis. 2011;69:145–52.PubMedCrossRefGoogle Scholar
  154. 154.
    Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto T, Kawano S, et al. Diagnostic accuracy of serum 1,3-β-d-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50:7.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521–7.PubMedCrossRefGoogle Scholar
  156. 156.
    Safrin S, Finkelstein DM, Feinberg J, Frame P, Simpson G, Wu A, et al. Comparison of three regimens for treatment of mild to moderate pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 study group. Ann Intern Med. 1996;124:792–802.PubMedCrossRefGoogle Scholar
  157. 157.
    Smego RA Jr, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for pneumocystis carinii pneumonia. Arch Intern Med. 2001;161:1529–33.PubMedCrossRefGoogle Scholar
  158. 158.
    Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev. 2006;(4):CD006150.Google Scholar
  159. 159.
    Bozzette SA, Morton SC. Reconsidering the use of adjunctive corticosteroids in pneumocystis pneumonia? J Acquir Immune Defic Syndr Hum Retrovirol: Official Publication of the International Retrovirology Association. 1995;8:345–7.Google Scholar
  160. 160.
    Kirk PM, Cannon PF, Minter DW, Stalpers JA, editors. Ainsworth and Bisbys dictionary of the fungi. 10th ed. CABI Publishing; 2008. xi + 771 pp.Google Scholar
  161. 161.
    Son V, Khue P, Strobel M. Penicilliosis and AIDS in Haiphong, Vietnam: evolution and predictive factors of death. Med Mal Infect. 2014;44:495–501.PubMedCrossRefGoogle Scholar
  162. 162.
    Segretain G. Description d’une nouvelle espece de Penicillium: Penicillium marneffei. Bull Soc Mycol. 1959;75:412–6.Google Scholar
  163. 163.
    DiSalvo AE, Fickling AM, Ajello L. Infection caused by Penicillium mameffei: a description of first natural infection in man. Am J Clin Path. 1973;60:259–63.PubMedCrossRefGoogle Scholar
  164. 164.
    Sirisanthana T, Supparatpinyo K. Epidemiology and management of penicilliosis in human immunodeficiency virus-infected patients. Int J Infect Dis. 1998;3(1):48–53.PubMedCrossRefGoogle Scholar
  165. 165.
    Skoulidis F, Morgan MS, MacLeod KM. Penicillium marneffei: a pathogen on our doorstep? J R Soc Med. 2004;97:394–6.PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Vanittanakom N, Jr CRC, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006;19:95–110.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Lavy D, Morin O, Venet G, Maugars Y, Prost A, Berthelot J-M. Pseudallescheria boydii knee arthritis in a young immunocompetent adult two years after a compound patellar fracture. Joint Bone Spine. 2001;68:517–20.PubMedCrossRefGoogle Scholar
  168. 168.
    Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis. 1996;23:125–30.PubMedCrossRefGoogle Scholar
  169. 169.
    Hospenthal DR. Uncommon fungi and related species. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia: Elsevier, Saunders; 2015. p. 3003–15.Google Scholar
  170. 170.
    Supparatpinyo K, Khamwan C, Baosoung V, Sirisanthana T, Nelson K. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet. 1994;344:110–3.PubMedCrossRefGoogle Scholar
  171. 171.
    Deng Z, Ribas JL, Gibson DW, Connor DH. Infections caused by Penicillium marneffei in China and Southeast Asia: review of eighteen published cases and report of four more Chinese cases. Rev Infect Dis. 1988;10:640–52.PubMedCrossRefGoogle Scholar
  172. 172.
    Chaiyaroj SC, Chawengkirttikul R, Sirisinha S, Watkins P, Srinoulprasert Y. Antigen detection assay for identification of Penicillium marneffei infection. J Clin Microbiol. 2003;41:432–4.PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Desakorn V, Simpson AJH, Wuthiekanun V, Sahassananda D, Rajanuwong A, Pitisuttithum P, et al. Development and evaluation of rapid urinary antigen detection tests for diagnosis of Penicilliosis marneffei. J Clin Microbiol. 2002;40:3179–83.PubMedPubMedCentralCrossRefGoogle Scholar
  174. 174.
    Sekhon AS, Li JS, Garg AK. Penicillium marneffei: serological and exoantigens studies. Mycopathologia. 1982;77:51–7.PubMedCrossRefGoogle Scholar
  175. 175.
    Yuen K, Wong S, Chau P, Tsang D. Serodiagnosis of Penicillium marneffei infection. Lancet. 1994;344:444–5.PubMedCrossRefGoogle Scholar
  176. 176.
    Vanittanakom N, Mekaprateep M, Sittisombut N, Supparatpinyo K, Kanjanasthiti P, Nelson K, et al. Western immunoblot analysis of protein antigens of Penicillium marneffei. Med Mycol. 1997;35:123–31.CrossRefGoogle Scholar
  177. 177.
    Supparatpinyo K, Nelson KE, Merz WG, Breslin BJ, Jr CRC, Kamwan C, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother. 1993;37:2407–11.PubMedPubMedCentralCrossRefGoogle Scholar
  178. 178.
    Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;26:1107–10.PubMedCrossRefGoogle Scholar
  179. 179.
    Chaiwarith R, Charoenyos N, Sirisanthana T, Supparatpinyo K. Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART. AIDS. 2007;21:365.PubMedCrossRefGoogle Scholar
  180. 180.
    Savioli L. World Health Organization (WHO): Schistosomiasis: Progress Report 2001–2011, Strategic Plan 2012–2013. 2013.Google Scholar
  181. 181.
    Leite LA, Pimenta Filho AA, Martins da Fonseca CS, Santana dos Santos B, Ferreira Rde C, Montenegro SM, et al. Hemostatic dysfunction is increased in patients with hepatosplenic schistosomiasis mansoni and advanced periportal fibrosis. PLoS Negl Trop Dis. 2013;7:e2314.PubMedPubMedCentralCrossRefGoogle Scholar
  182. 182.
    Muller R. Human schistosomiasis. Jordan P, Webbe G, Sturrock RF, editors. J Helminthol. 1995;69:95.Google Scholar
  183. 183.
    Pinto-Almeida A, Mendes T, Armada A, Belo S, Carrilho E, Viveiros M, et al. The role of efflux pumps in Schistosoma mansoni Praziquantel resistant phenotype. PLoS One. 2015;10:e0140147.PubMedPubMedCentralCrossRefGoogle Scholar
  184. 184.
    Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368:1106–18.PubMedCrossRefGoogle Scholar
  185. 185.
    Maguire JH. Trematodes (Schistosomes and liver, intestinal, and lung flukes). In: Bennett JE, Dolin R, Blaser M, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier, Saunders; 2015. p. 3316–26.Google Scholar
  186. 186.
    Gryseels B, Polderman A. The morbidity of schistosomiasis mansoni in Maniema (Zaire). Trans R Soc Trop Med Hyg. 1987;81:202–9.PubMedCrossRefGoogle Scholar
  187. 187.
    Lambertucci RL. Schistosoma mansoni: pathological and clinical aspects. In: Jordan P, Webbe G, Sturrock FS, editors. Human schistosomiasis. Wallingford: CAB International; 1993. p. 195–235.Google Scholar
  188. 188.
    Gryseels B. Morbidity due to infection with Schistosoma mansoni: an update. Trop Geogr Med. 1992;44:189.PubMedGoogle Scholar
  189. 189.
    Kardorff R, Stelma FF, Vocke A-K, Yazdanpanah Y, Thomas AK, Mbaye A, et al. Ultrasonography in a Senegalese community recently exposed to Schistosoma mansoni infection. Am J Trop Med Hyg. 1996;54:586–90.PubMedCrossRefGoogle Scholar
  190. 190.
    Mies S, Neto O, Beer A, Baia C, Alfieri F, Pereira L, et al. Systemic and hepatic hemodynamics in hepatosplenic Manson’s schistosomiasis with and without propranolol. Dig Dis Sci. 1997;42:751–61.PubMedCrossRefGoogle Scholar
  191. 191.
    Filgueira NA, de CMA S, Juca NT, Bezerra MF, Lacerda CM. Schistosomal liver fibrosis and hepatocellular carcinoma – case series of patients submitted to liver transplantation. Braz J Infect Dis. 2018;22:352–4.PubMedCrossRefGoogle Scholar
  192. 192.
    Lambertucci JR, Drummond SC, Voieta I, de Queiroz LC, Pereira PPN, Chaves BA, et al. An outbreak of acute Schistosoma mansoni schistosomiasis in a nonendemic area of Brazil: a report on 50 cases, including 5 with severe clinical manifestations. Clin Infect Dis. 2013;57:E1–e6.PubMedCrossRefGoogle Scholar
  193. 193.
    de Jesus AR, Silva A, Santana LB, Magalhaes A, de Jesus AA, de Almeida RP, et al. Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J Infect Dis. 2002;185:98–105.PubMedCrossRefGoogle Scholar
  194. 194.
    Doherty JF, Moody AH, Wright SG. Lesson of the week: Katayama fever: an acute manifestation of schistosomiasis. BMJ. 1996;313:1071.PubMedPubMedCentralCrossRefGoogle Scholar
  195. 195.
    Cheever AW. A quantitative post-mortem study of schistosomiasis mansoni in man. Am J Trop Med Hyg. 1968;17:38–64.PubMedCrossRefGoogle Scholar
  196. 196.
    Chen MG. Schistosoma japonicum and S japonicum-like infections: epidemiology, clinical and pathological aspects. In: Jordan P, Webbe G, Sturrock FS, editors. Human schistosomiasis. Wallingford: CAB International; 1993. p. 237–70.Google Scholar
  197. 197.
    Lambertucci JR. Revisiting the concept of hepatosplenic schistosomiasis and its challenges using traditional and new tools. Rev Soc Bras Med Trop. 2014;47:130–6.PubMedCrossRefGoogle Scholar
  198. 198.
    Marti AI, Colombe S, Masikini PJ, Kalluvya SE, Smart LR, Wajanga BM, et al. Increased hepatotoxicity among HIV-infected adults co-infected with Schistosoma mansoni in Tanzania: A cross-sectional study. PLoS Negl Trop Dis. 2017;11:e0005867.PubMedPubMedCentralCrossRefGoogle Scholar
  199. 199.
    Camacho-Lobato L, Borges DR. Early liver dysfunction in schistosomiasis. J Hepatol. 1998;29:233–40.PubMedCrossRefGoogle Scholar
  200. 200.
    Tsang VCW, Wilkins PP. Immunodiagnosis of schistosomiasis. Immunol Investig. 1997;26:175–88.CrossRefGoogle Scholar
  201. 201.
    Clerinx J, Van Gompel A. Schistosomiasis in travellers and migrants. Travel Med Infect Dis. 2010;9:6–24.CrossRefGoogle Scholar
  202. 202.
    Chiavaroli R, Grima P. Detection of early liver fibrosis in patients with intestinal schistosomiasis: sonographic and histologic findings in Schistosoma mansoni infection. Infection. 2008;36:585–9.PubMedCrossRefGoogle Scholar
  203. 203.
    Wu W, Wang W, Huang Y. New insight into praziquantel against various developmental stages of schistosomes. Parasitol Res. 2011;109:1501–7.PubMedCrossRefGoogle Scholar
  204. 204.
    Guisse F, Polman K, Stelma FF, Mbaye A, Talla I, Niang M, et al. Therapeutic evaluation of two different dose regimens of Praziquantel in a recent Schistosoma mansoni focus in northern Senegal. Am J Trop Med Hyg. 1997;56:511–4.PubMedCrossRefGoogle Scholar
  205. 205.
    King CH, Wiper DW III, De Stigter KV, Peters PA, Koech D, Ouma JH, et al. Dose-finding study for praziquantel therapy of Schistosoma haematobium in Coast Province, Kenya. Am J Trop Med Hyg. 1989;40:507–13.PubMedCrossRefGoogle Scholar
  206. 206.
    Ross AG, Vickers D, Olds GR, Shah SM, McManus DP. Katayama syndrome. Lancet Infect Dis. 2007;7:218–24.PubMedCrossRefGoogle Scholar
  207. 207.
    Lam NS, Long X, Su X, Lu F. Artemisinin and its derivatives in treating helminthic infections beyond schistosomiasis. Pharmacol Res. 2018;133:77–100.PubMedCrossRefGoogle Scholar
  208. 208.
    Hegazy LAM, Motiam MHA, Abd El-Aal NF, Ibrahim SM, Mohamed HK. Evaluation of artesunate and praziquantel combination therapy in murine. Iran J Parasitol. 2018;13:193.PubMedPubMedCentralGoogle Scholar
  209. 209.
    del Villar LP, Burguillo FJ, Lopez-Aban J, Muro A. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One. 2012;7:e45867.CrossRefGoogle Scholar
  210. 210.
    Miranda MAC, Bandeira FAA, Domingues ALC, Chaves RCM, Juca N, da Mota DL. Improvement of schistosomal portal hypertensive colopathy after surgical treatment. Arq Gastroenterol. 2013;50:153–6.PubMedCrossRefGoogle Scholar
  211. 211.
    Leite LA, Pimenta Filho AA, Ferreira Rde C, da Fonseca CS, dos Santos BS, Montenegro SM, et al. Splenectomy improves hemostatic and liver functions in hepatosplenic schistosomiasis mansoni. PLoS One. 2015;10:e0135370.PubMedPubMedCentralCrossRefGoogle Scholar
  212. 212.
    Utzinger J, N’goran EK, N’dri A, Lengeler C, Tanner M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Tropical Med Int Health. 2000;5:771–8.CrossRefGoogle Scholar
  213. 213.
    Mateen FJ, Newstead JC, McClean KL. Bacillary angiomatosis in an HIV-positive man with multiple risk factors: a clinical and epidemiological puzzle. Can J Infect Dis Med Microbiol = Journal canadien des maladies infectieuses et de la microbiologie medicale. 2005;16:249–52.PubMedCrossRefGoogle Scholar
  214. 214.
    Cunningham ET, Koehler JE. Ocular bartonellosis. Am J Ophthalmol. 2000;130:340–9.PubMedCrossRefGoogle Scholar
  215. 215.
    Koehler JE, Glaser CA, Tappero JW. Rochalimaea henselae infection: a new zoonosis with the domestic cat as reservoir. JAMA. 1994;271:531–5.PubMedCrossRefGoogle Scholar
  216. 216.
    Chomel BB, Molia S, Kasten RW, Borgo GM, Stuckey MJ, Maruyama S, et al. Isolation of Bartonella henselae and two new Bartonella subspecies, Bartonella koehlerae Subspecies boulouisii subsp nov and Bartonella koehlerae Subspecies bothieri subsp nov from Free-Ranging Californian Mountain Lions and Bobcats. PloS One. 2016;11:e0148299.PubMedPubMedCentralCrossRefGoogle Scholar
  217. 217.
    Demers DM, Bass JW, Vincent JM, Person DA, Noyes DK, Staege CM, et al. Cat-scratch disease in Hawaii: etiology and seroepidemiology. J Pediatr. 1995;127:23–6.PubMedCrossRefGoogle Scholar
  218. 218.
    Gandhi TN, Slater LN, Welch DF, Koehler JE. Bartonella, including cat-scratch disease. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Philadelphia: Elsevier, Saunders; 2015. p. 2549–663.Google Scholar
  219. 219.
    Koehler JE, Sanchez MA, Garrido CS, Whitfeld MJ, Chen FM, Berger TG, et al. Molecular epidemiology of Bartonella infections in patients with bacillary angiomatosis-peliosis. N Engl J Med. 1997;337:1876–83.PubMedCrossRefGoogle Scholar
  220. 220.
    Scott C, Azwa A, Cohen C, McIntyre M, Desmond N. Cat scratch disease: a diagnostic conundrum. Int J STD AIDS. 2009;20:585–6.PubMedCrossRefGoogle Scholar
  221. 221.
    Joncour AL, Bidegain F, Ziol M, Galicier L, Oksenhendler E, Mechai F, et al. Hemophagocytic Lymphohistiocytosis associated with Bartonella henselae infection in an HIV-infected patient. Clin Infect Dis. 2016;62:804.PubMedCrossRefGoogle Scholar
  222. 222.
    Mantis J, Ali Y, Junejo SZ. Cat-scratch disease in an AIDS patient presenting with generalized lymphadenopathy: an unusual presentation with delayed diagnosis. Am J Case Rep. 2018;19:906–11.PubMedPubMedCentralCrossRefGoogle Scholar
  223. 223.
    Mohle-Boetani JC, Koehler JE, Berger TG, LeBoit PE, Kemper CA, Reingold AL, et al. Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study. Clin Infect Dis. 1996;22:794–800.PubMedCrossRefGoogle Scholar
  224. 224.
    Perkocha LA, Geaghan SM, Yen TSB, Nishimura SL, Chan SP, Garcia-Kennedy R, et al. Clinical and pathological features of bacillary peliosis hepatis in association with human immunodeficiency virus infection. N Engl J Med. 1990;323:1581–6.PubMedCrossRefGoogle Scholar
  225. 225.
    Garcia JC, Nunez MJ, Castro B, Fernandez JM, Portillo A, Oteo JA. Hepatosplenic cat scratch disease in immunocompetent adults. Medicine. 2014;93:267–79.PubMedPubMedCentralCrossRefGoogle Scholar
  226. 226.
    Verma SK, Martin A, Montero JA. Atypical cat scratch disease with Hepatosplenic involvement. Clin Gastroenterol Hepatol. 2017;15:5–6.CrossRefGoogle Scholar
  227. 227.
    Koehler JE, Sanchez MA, Tye S, Garrido-Rowland CS, Chen FM, Maurer T, et al. Prevalence of Bartonella infection among human immunodeficiency virus-infected patients with fever. Clin Infect Dis. 2003;37:559–66.PubMedCrossRefGoogle Scholar
  228. 228.
    Mallqui V, Speelmon EC, Verastegui M, Maguina-Vargas C, Pinell-Salles P, Lavarello R, et al. Sonicated diagnostic immunoblot for Bartonellosis. Clin Diagn Lab Immunol. 2000;7:1–5.PubMedPubMedCentralGoogle Scholar
  229. 229.
    Zeaiter Z, Fournier P-E, Greub G, Raoult D. Diagnosis of Bartonella endocarditis by a real-time nested PCR assay using serum. J Clin Microbiol. 2003;41:919–25.PubMedPubMedCentralCrossRefGoogle Scholar
  230. 230.
    Rolain J-M, Foucault C, Guieu R, Scola BL, Brouqui P, Raoult D. Bartonella quintana in human erythrocytes. Lancet. 2002;360:226–8.PubMedCrossRefGoogle Scholar
  231. 231.
    Okaro U, Addisu A, Casanas B, Anderson B. Bartonella species, an emerging cause of blood-culture-negative endocarditis. Clin Microbiol Rev. 2017;30:709–46.PubMedPubMedCentralCrossRefGoogle Scholar
  232. 232.
    Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep: Morbidity and Mortality Weekly Report Recommendations and reports. 2009;58:1–207.. CE1–4PubMedGoogle Scholar
  233. 233.
    Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother. 2004;48:1921–33.PubMedPubMedCentralCrossRefGoogle Scholar
  234. 234.
    Koehler JE, Tappero JW. Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus. Clin Infect Dis. 1993;17:612–24.PubMedCrossRefGoogle Scholar
  235. 235.
    Hickey AJ, Gounder L, Moosa M-YS, Drain PK. A systematic review of hepatic tuberculosis with considerations in human immunodeficiency virus co-infection. BMC Infect Dis. 2015;15:209.PubMedPubMedCentralCrossRefGoogle Scholar
  236. 236.
    Bristowe JS. On the connection between abscess of the liver and gastrointestinal ulceration. Trans Pathol Coc London. 1858;9:241–52.Google Scholar
  237. 237.
    Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004;120:316.PubMedGoogle Scholar
  238. 238.
    Amarapurkar DN, Patel ND, Amarapurkar AD. Hepatobiliary tuberculosis in western India. Indian J Pathol Microbiol. 2008;51:175–81.PubMedCrossRefGoogle Scholar
  239. 239.
    Jones BE, Young S, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med. 1993;148:1292–7.Google Scholar
  240. 240.
    Hersh C. Tuberculosis of the liver. A study of 200 cases. S Afr Med J. 1964;38:857.Google Scholar
  241. 241.
    Wang J-Y, Lee L-N, Luh K-T, Yang P-C, Jan I-S, Hsueh P-R, et al. Disseminated tuberculosis: a 10-year experience in a medical center. Medicine. 2007;86:39.PubMedCrossRefGoogle Scholar
  242. 242.
    Amarapurkar AD, Sangle NA. Histological spectrum of liver in HIV - autopsy study. Ann Hepatol. 2005;4:47.PubMedGoogle Scholar
  243. 243.
    Chien RN, Lin PY, Liaw YF. Hepatic tuberculosis: comparison of miliary and local form. Infection. 1995;23:5–8.PubMedCrossRefGoogle Scholar
  244. 244.
    Wei-Chen T, Chung-Mou K, Chen-Hsiang L, Seng-Kee C, Chao-Chen H, Tsung-Hui H, et al. Tuberculosis in Southern Taiwan: 15-years clinical experience. 內科學誌. 2008;19:410–7.Google Scholar
  245. 245.
    Kok KYY, Yapp SKS. Isolated hepatic tuberculosis: report of five cases and review of the literature. J Hep Bil Pancr Surg. 1999;6:195–8.CrossRefGoogle Scholar
  246. 246.
    Vilaichone R, Machachai V. Hepatic tuberculosis: a clinico-pathological study. Thai J Gastroenterol. 2004;5:19–23.Google Scholar
  247. 247.
    Spiegel CT, Tuazon CU. Tuberculous liver abscess. Tubercle. 1984;65:127–31.PubMedCrossRefGoogle Scholar
  248. 248.
    Reed DH, Nash AF, Valabhji P. Radiological diagnosis and management of a solitary tuberculous hepatic abscess. Br J Radiol. 1990;63:902–4.PubMedCrossRefGoogle Scholar
  249. 249.
    Singh S, Jain P, Aggarwal G, Dhiman P, Singh S, Sen R. Primary hepatic tuberculosis: a rare but fatal clinical entity if undiagnosed. Asian Pac J Trop Med. 2012;5:498–9.PubMedCrossRefGoogle Scholar
  250. 250.
    Manoj EM, Srigrishna R, Ragunathan MK. Hepatic tuberculosis presenting with extreme hyperferritinemia masquerading as adult-onset Still’s disease: a case report. J Med Case Rep. 2012;6:195.PubMedPubMedCentralCrossRefGoogle Scholar
  251. 251.
    Hsieh T-C, Wu Y-C, Hsu C-N, Yang C-F, Chiang I-P, Hsieh C-Y, et al. Hepatic macronodular tuberculoma mimics liver metastasis in a patient with locoregional advanced tongue cancer. J Clin Oncol. 2011;29:e641–3.PubMedCrossRefGoogle Scholar
  252. 252.
    Bharathi A, Nagarjuna K, Prasad G, Reddy JB, PDK R. Tuberculoma of the liver. J Indian Assoc Pediatr Surg. 2009;13:149.CrossRefGoogle Scholar
  253. 253.
    Zhu C, Liu Z, Li Z, Mei S, Hu Z. The performance and limitation of T-SPOT.TB for the diagnosis of TB in a high prevalence setting. J Thorac Dis. 2014;6:713.PubMedPubMedCentralGoogle Scholar
  254. 254.
    Nash DR, Douglass JE. Anergy in active pulmonary tuberculosis. A comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses. Chest. 1980;77:32.PubMedCrossRefGoogle Scholar
  255. 255.
    Elzi L, Steffen I, Furrer H, Fehr J, Cavassini M, Hirschel B, et al. Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB(TM)) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection. BMC Infect Dis. 2011;11:319.PubMedPubMedCentralCrossRefGoogle Scholar
  256. 256.
    Fisk TL, Hon H-M, Lennox JL, von Reyn CF, Horsburgh CJ. Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS. 2003;17:1102–5.PubMedCrossRefGoogle Scholar
  257. 257.
    Purl AS, Nayyar AK, Vij JC. Hepatic tuberculosis. Indian J Tuberc. 1994;41:131–4.Google Scholar
  258. 258.
    Grant AJ, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. BMJ. 1999;45 Suppl 4:IV1–IV11.Google Scholar
  259. 259.
    Gounder L, Moodley P, Drain PK, Hickey AJ, Moosa M-YS. Hepatic tuberculosis in human immunodeficiency virus co-infected adults: a case series of South African adults. BMC Infect Dis. 2017;17:115. London: BioMed Central.PubMedPubMedCentralCrossRefGoogle Scholar
  260. 260.
    Diaz ML, Herrera T, Lopez-Vidal Y, Calva JJ, Hernandez R, Palacios GR, et al. Polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA in tissue and assessment of its utility in the diagnosis of hepatic granulomas. J Lab Clin Med. 1996;127:359–63.PubMedCrossRefGoogle Scholar
  261. 261.
    Organization WH. Policy statement : automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva: World Health Organization. 2011.Google Scholar
  262. 262.
    Scott LE, Beylis N, Nicol M, Nkuna G, Molapo S, Berrie L, et al. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. J Clin Microbiol. 2014;52:1818–23.PubMedPubMedCentralCrossRefGoogle Scholar
  263. 263.
    Garcia-Basteiro AL, Ismail MR, Carrilho C, Ussene E, Castillo P, Chitsungo D, et al. The role of Xpert MTB/RIF in diagnosing pulmonary tuberculosis in post-mortem tissues. Sci Rep. 2016;6:20703.PubMedPubMedCentralCrossRefGoogle Scholar
  264. 264.
    Chong VH, Lim KS. Hepatobiliary tuberculosis. Singap Med J. 2010;51:744.Google Scholar
  265. 265.
    Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:E147–e195.PubMedCrossRefGoogle Scholar
  266. 266.
    Hwang SW, Kim YJ, Cho EJ, Choi JK, Kim SH, Yoon J-H, et al. Clinical features of hepatic tuberculosis in biopsy-proven cases. Korean J Hepatol. 2009;15:159–67.PubMedCrossRefGoogle Scholar
  267. 267.
    Desai CS, Joshi AG, Abraham P, Desai DC, Deshpande RB, Bhaduri A, et al. Hepatic tuberculosis in absence of disseminated abdominal tuberculosis. Ann Hepatol. 2006;5:41–3.PubMedGoogle Scholar
  268. 268.
    Alvarez SZ, Carpio R. Hepatobiliary tuberculosis. Dig Dis Sci. 1983;28:193–200.PubMedCrossRefGoogle Scholar
  269. 269.
    Maharaj B, Leary WP, Pudifin DJ. A prospective study of hepatic tuberculosis in 41 black patients. Q J Med. 1987;63:517.PubMedGoogle Scholar
  270. 270.
    Rihana NA, Kandula M, Velez A, Dahal K, O’Neill EB. Histoplasmosis presenting as granulomatous hepatitis: case report and review of the literature. Case Rep Med. 2014;2014:879535–4.PubMedPubMedCentralCrossRefGoogle Scholar
  271. 271.
    Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis. 2004;38:1485–9.PubMedCrossRefGoogle Scholar
  272. 272.
    Blair J, Coakley B, Santelli A, Hentz J, Wengenack N. Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts. Mycopathologia. 2006;162:317–24.PubMedPubMedCentralCrossRefGoogle Scholar
  273. 273.
    Andersson J. An overview of Epstein-Barr virus: from discovery to future directions for treatment and prevention. Herpes. 2000;7:76–82.PubMedGoogle Scholar
  274. 274.
    Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481–92.CrossRefGoogle Scholar
  275. 275.
    Petrara MR, Freguja R, Gianesin K, Zanchetta M, De Rossi A. Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection, vol. 4. Switzerland: Frontiers Media S.A; 2013. p. 311.Google Scholar
  276. 276.
    Cote TR, Biggar RJ, Rosenberg PS, et al. Non=Hodgkin’s lymphoma among people with AIDS: incidence, presentation, and public health burden. AIDS/Cancer study group. Int J Cancer. 1997;73(5):645.PubMedCrossRefGoogle Scholar
  277. 277.
    MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991;338(8773):969.CrossRefGoogle Scholar
  278. 278.
    Petrova M, Kamburov V. Epstein-Barr virus: silent companion or causative agent in chronic liver disease? World J Gastroenterol. 2010;16(33):4130–4.PubMedPubMedCentralCrossRefGoogle Scholar
  279. 279.
    Mellinger JL, Rossaro L, Naugler WE, et al. Epstein-Barr Virus (EBV) related acute liver failure: a case series from the US acute liver failure study group. Dig Dis Sci. 2014;59(7):1630–7.PubMedPubMedCentralCrossRefGoogle Scholar
  280. 280.
    Negro F. The paradox of Epstein-Barr virus associated hepatitis. J Hepatol. 2006;44:839–41.PubMedCrossRefGoogle Scholar
  281. 281.
    Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol. 1990;154:125–70. Germany.PubMedGoogle Scholar
  282. 282.
    Klemola E, Kaariainen L, von Essen R, Haltia K, Koivuniemi A, von Bonsdorff CH. Further studies on cytomegalovirus mononucleosis in previously healthy individuals. J Intern Med. 1967;182:311–22. Sweden.Google Scholar
  283. 283.
    Klemola E, von Essen R, Henle G, Henle W. Infectious-mononucleosis-like disease with negative Heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis. 1970;121:608–14. United States: University of Chicago Press.PubMedCrossRefGoogle Scholar
  284. 284.
    Carter AR. Cytomegalovirus disease presenting as hepatitis. Br Med J. 1968;3:786. England: British Medical Association.PubMedPubMedCentralCrossRefGoogle Scholar
  285. 285.
    Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis. 1992;166:1223–7. University of Chicago Press.PubMedCrossRefGoogle Scholar
  286. 286.
    Kim JY, Singer EJ, Klausner JD, Bonelli L. A case of primary HIV type 1 and cytomegalovirus coinfection presenting with widespread clinical disease. J Int Assoc Provid AIDS Care. 2014;13:196. Sage Publications, Inc.PubMedPubMedCentralCrossRefGoogle Scholar
  287. 287.
    Hong K-W, Kim S, Kim Y, Wie S, Kim Y, Yoo J-H, et al. Acute cytomegalovirus pneumonia and hepatitis presenting during acute HIV retroviral syndrome. Infection. 2011;39:155–9. Berlin/Heidelberg: Springer-Verlag.PubMedCrossRefGoogle Scholar
  288. 288.
    Albaadani A, Alhumaidi S, Asiri S. Cytomegalovirus hepatitis in HIV infection. J Med Cases. 2016;7:403–5.CrossRefGoogle Scholar
  289. 289.
    Collier AC, Meyers JD, Corey L, Murphy VL, Roberts PL, Handsfield HH. Cytomegalovirus infection in homosexual men: relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. Am J Med. 1987;82:593–601. United States: Elsevier Inc.PubMedCrossRefGoogle Scholar
  290. 290.
    Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91:119–26. United States: Elsevier Inc.PubMedCrossRefGoogle Scholar
  291. 291.
    Sherman S, Eytan O, Justo D. Thrombosis associated with acute cytomegalovirus infection: a narrative review. Arch Med Sci. 2014;10:1186–90. Poland: Termedia Publishing House.PubMedPubMedCentralCrossRefGoogle Scholar
  292. 292.
    Nakase H, Herfarth H. Cytomegalovirus colitis, cytomegalovirus hepatitis and systemic cytomegalovirus infection: common features and differences. Inflamm Intest Dis. 2016;1:15–23. Basel, Switzerland: S. Karger AG.PubMedPubMedCentralCrossRefGoogle Scholar
  293. 293.
    Bonkowsky HL, Lee RV, Klatskin G. Acute granulomatous hepatitis: occurrence in cytomegalovirus mononucleosis. JAMA. 1975;233:1284–8. United States: American Medical Association.PubMedCrossRefGoogle Scholar
  294. 294.
    Hinnant KL, Rotterdam HZ, Bell ET, Tapper ML. Cytomegalovirus infection of the alimentary tract: a clinicopathological correlation. Am J Gastroenterol. 1986;81:944–50. United States.PubMedGoogle Scholar
  295. 295.
    Culpepper-Morgan JA, Kotler DP, Scholes JV, Tierney AR. Evaluation of diagnostic criteria for mucosal cytomegalic inclusion disease in the acquired immune deficiency syndrome. Am J Gastroenterol. 1987;82:1264–70. United States.PubMedGoogle Scholar
  296. 296.
    Wilcox CM, Diehl DL, Cello JP, Margaretten W, Jacobson MA. Cytomegalovirus esophagitis in patients with AIDS. A clinical, endoscopic, and pathologic correlation. Ann Intern Med. 1990;113:589. United States: American College of Physicians.PubMedCrossRefGoogle Scholar
  297. 297.
    Jabs DA. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the ganciclovir Cidofovir cytomegalovirus retinitis trial. Am J Ophthalmol. 2001;131:457–67. United States: Elsevier Inc.CrossRefGoogle Scholar
  298. 298.
    Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. Arch Intern Med. 1998;158:957–69. Chicago: American Medical Association.PubMedPubMedCentralCrossRefGoogle Scholar
  299. 299.
    Dieterich DT, Poles MA, Lew EA, Martin-Munley S, Johnson J, Nix D, et al. Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. Antimicrob Agents Chemother. 1997;41:1226–30. United States: American Society for Microbiology.PubMedPubMedCentralCrossRefGoogle Scholar
  300. 300.
    Blanshard C, Benhamou Y, Dohin E, Lernestedt J-O, Gazzard BG, Katlama C. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis. 1995;172:622–8. United States: University of Chicago Press.PubMedCrossRefGoogle Scholar
  301. 301.
    Blanshard C. Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet. J Acquir Immune Defic Syndr. 1992;5 Suppl 1:S25–8. United States: Lippincott Williams & Wilkins, WK Health.Google Scholar
  302. 302.
    Afani SA, Perez CC, Vasquez TP, Wolff RM. Guidelines on HIV/AIDS. Rev Chilena Infectol. 2010;27:197. Chile.CrossRefGoogle Scholar
  303. 303.
    Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex Virus-2 on HIV-1 acquisition and transmission: A review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35:435–45. Hagerstown: Lippincott Williams & Wilkins Ovid Technologies.PubMedCrossRefGoogle Scholar
  304. 304.
    Tapper E, Curry M. Hepatitis caused by other virus. 4th ed: Elsevier; 2017. p. 78–81.Google Scholar
  305. 305.
    Farr RW, Short S, Weissman D. Fulminant hepatitis during herpes simplex virus infection in apparently immunocompetent adults: report of two cases and review of the literature. Clin Infect Dis. 1997;24:1191–4. United States: University of Chicago Press.PubMedCrossRefGoogle Scholar
  306. 306.
    Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32:1481–6. United States: University of Chicago Press.PubMedPubMedCentralCrossRefGoogle Scholar
  307. 307.
    Dunic I, Djurkovic-Djakovic O, Vesic S. Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors. Int J STD AIDS. 2005;16:475–88.PubMedCrossRefGoogle Scholar
  308. 308.
    Kusne S, Pappo O, Manez R, Pazin G, Carpenter B, Fung JJ, et al. Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients. Transplantation. 1995;60:619–21. United States.PubMedPubMedCentralCrossRefGoogle Scholar
  309. 309.
    Leung J, Harpaz R, Baughman AL, Heath K, Loparev V, Vazquez M, et al. Evaluation of laboratory methods for diagnosis of varicella. Clin Infect Dis. 2010;51:23–32. Oxford: University of Chicago Press.PubMedCrossRefGoogle Scholar
  310. 310.
    Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 2008;21:704–15. United States: American Society for Microbiology.PubMedPubMedCentralCrossRefGoogle Scholar
  311. 311.
    Wang WH, Wang HL. Fulminant adenovirus hepatitis following bone marrow transplantation. A case report and brief review of the literature. Arch Pathol Lab Med. 2003;127:e246. United States: College of American Pathologists.PubMedGoogle Scholar
  312. 312.
    Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, et al. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis. 2002;2:281–92. London: Elsevier Ltd.PubMedCrossRefGoogle Scholar
  313. 313.
    Van Leer-Greenberg B, Kole A, Chawla S. Hepatic Kaposi sarcoma: a case report and review of the literature. World J Hepatol. 2017;9:171–9. United States: Baishideng Publishing Group Inc.PubMedPubMedCentralCrossRefGoogle Scholar
  314. 314.
    Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. Clin Microbiol Rev. 1997;10:521–67. United States: American Society for Microbiology.PubMedPubMedCentralCrossRefGoogle Scholar
  315. 315.
    Harma M, Hockerstedt K, Lautenschlager I. Human herpesvirus-6 and acute liver failure1. Transplantation. 2003;76:536–9.PubMedCrossRefGoogle Scholar
  316. 316.
    Concise Communications. Wiley-Blackwell. 2001;7:275–82.Google Scholar
  317. 317.
    Fairfax MR, Schacker T, Cone RW, Collier AC, Corey L. Human herpesvirus 6 DNA in blood cells of human immunodeficiency virus-infected men: correlation of high levels with high CD4 cell counts. J Infect Dis. 1994;169:1342–5. United States: University of Chicago Press.PubMedCrossRefGoogle Scholar
  318. 318.
    Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society–USA panel. JAMA. 2016;316:191–210.PubMedPubMedCentralCrossRefGoogle Scholar
  319. 319.
    Lo Vecchio A, Giannattasio A, Guarino A. HIV and the intestine. In: Guandalini S, Dhawan A, Branski D, editors. Textbook of pediatric gastroenterology, hepatology and nutrition. Cham: Springer; 2015.Google Scholar
  320. 320.
    Wambani JR, Ogola PE. Anti-retroviral drug hepatotoxicity and risk factors in HIV patients with or without hepatitis B and C: A review. J Infect Dis Ther. 2015;3:2332-0877.Google Scholar
  321. 321.
    Nunez M, Lana R, Luis Mendoza J, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:426–31.PubMedCrossRefGoogle Scholar
  322. 322.
    Kovari H, Weber R. Influence of antiretroviral therapy on liver disease. Curr Opin HIV AIDS. 2011;6:272–7. United States: Lippincott Williams & Wilkins, Inc.PubMedCrossRefGoogle Scholar
  323. 323.
    Ortiz R, DeJesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22:1389–97. England.PubMedCrossRefGoogle Scholar
  324. 324.
    Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010;52:1143–55. Hoboken: Wiley Subscription Services, Inc., A Wiley Company.PubMedCrossRefGoogle Scholar
  325. 325.
    Soriano V, Puoti M, Garcia-Gasco P, Rockstroh JK, Benhamou Y, Barreiro P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13. England.PubMedCrossRefGoogle Scholar
  326. 326.
    Package insert zerit [Internet]. 2017. Available from:
  327. 327.
    Porche DJ. TOXLINE [Internet]. 2000. p. 72–5.Google Scholar
  328. 328.
    Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 2007;59:342–6. Oxford: Oxford University Press.PubMedCrossRefGoogle Scholar
  329. 329.
    Package insert Viramune. Germany. 2012.Google Scholar
  330. 330.
    Casado JL. Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine. 2013;15:139–45. Spain.Google Scholar
  331. 331.
    Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38:S90–7. United States: University of Chicago Press.PubMedCrossRefGoogle Scholar
  332. 332.
    Clinical and research information on drug-induced liver injury [Internet]. [cited 2018 Nov 20].Google Scholar
  333. 333.
    Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol. 2011;71:659–71. Oxford, UK: Blackwell Publishing Ltd.PubMedPubMedCentralCrossRefGoogle Scholar
  334. 334.
    Castro N, Braun J, Charreau I, Lafeuillade A, Viard J-P, Allavena C, et al. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial. AIDS Res Ther. 2016;13:17. BioMed Central.CrossRefPubMedPubMedCentralGoogle Scholar
  335. 335.
    Bickford CB. Correspondence. Baltimore: Johns Hopkins University Press; 2012.Google Scholar
  336. 336.
    Emerson ER, Post JJ, Workman C. A delayed hypersensitivity reaction to enfuvirtide after rechallenge. Int J STD AIDS. 2009;20:288–9.PubMedCrossRefGoogle Scholar
  337. 337.
    Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2016;128.Google Scholar
  338. 338.
    Haque T, Sasatomi E, Hayashi PH. Drug-induced liver injury: pattern recognition and future directions [internet]. Gut Liver. 2016;10(1):27–36. Korea (South): Editorial Office of Gut and Liver.PubMedPubMedCentralCrossRefGoogle Scholar
  339. 339.
    Tuberculosis Fact SHeet [Internet]. 2018.Google Scholar
  340. 340.
    Alffenaar J-WC, Tiberi S, Verbeeck RK, Heysell SK, Grobusch MP. Therapeutic drug monitoring in tuberculosis: practical application for physicians. Clin Infect Dis. 2017;64:104–5. United States.PubMedCrossRefGoogle Scholar
  341. 341.
    Daley CL, Chaisson LH, Barry PM, Sotgiu G, Grzemska M, Schaaf HS, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:853. University of Chicago Press.PubMedPubMedCentralCrossRefGoogle Scholar
  342. 342.
    Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2012;3:37–49. India: Elsevier B.V.PubMedPubMedCentralCrossRefGoogle Scholar
  343. 343.
    Fountain FF, Tolley E, Chrisman CR, Self SH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection. Chest. 2005;128:116–23.PubMedCrossRefGoogle Scholar
  344. 344.
    Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026–30. England: Eur Respiratory Soc.PubMedCrossRefGoogle Scholar
  345. 345.
    Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–7. United States: Am Thoracic Soc.PubMedCrossRefGoogle Scholar
  346. 346.
    Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–52. United States: Am Thoracic Soc.PubMedCrossRefGoogle Scholar
  347. 347.
    Kim WS, Lee SS, Lee CM, Kim HJ, Ha CY, Kim HJ, et al. Hepatitis C and not hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16:50. London: BioMed Central.PubMedPubMedCentralCrossRefGoogle Scholar
  348. 348.
    Chen L, Bao D, Gu L, Gu Y, Zhou L, Gao Z, et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis. 2018;18:295–10. London: BioMed Central.PubMedPubMedCentralCrossRefGoogle Scholar
  349. 349.
    Wong W, Wu P, Yuen M, Cheng C, Yew W, Wong P, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31:201–6. Philadelphia, PA: W.B. Saunders.PubMedCrossRefGoogle Scholar
  350. 350.
    Wang JY, Liu CH, Hu FC, chang HC. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect. 2011;62:448–55. England: Elsevier Ltd.PubMedCrossRefGoogle Scholar
  351. 351.
    Dworkin MS, Adams MR, Cohn DL, Davidson AJ, Buskin S, Horwitch C, et al. Factors that complicate the treatment of tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr. 2005;39:464–70. Hagerstown: Lippincott Williams & Wilkins Ovid Technologies.PubMedCrossRefGoogle Scholar
  352. 352.
    Costiniuk CT, Gosnell BI, Manzini TC. Tuberculous drug-induced liver injury and treatment re-challenge in human immunodeficiency virus co-infection. J Glob Infect Dis. 2015;7:151–6.PubMedPubMedCentralCrossRefGoogle Scholar
  353. 353.
    Tostmann A, Boeree MJ, Naarnoutse RE. Antituberculosis drug-induced hepatotoxicity:concise up-to-date review. J Gastroenterol Hepatol. 2007;23:192–202.PubMedCrossRefGoogle Scholar
  354. 354.
    Huang Y-S, Chern H-D, Su W-J, Wu J-C, Lai S-L, Yang S-Y, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug–induced hepatitis. Hepatology. 2002;35:883–9. Philadelphia, PA: Elsevier Inc.PubMedCrossRefGoogle Scholar
  355. 355.
    Roy B, Chowdhury A, Kundu S. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. J Gastroenterol Hepatol. 2001;16:1033–7.PubMedCrossRefGoogle Scholar
  356. 356.
    Drug-resistant tuberculosis: a survival guide for clinicians [internet]. 2016 [cited 2018 Nov 21].Google Scholar
  357. 357.
    Ho CC, Chen YC, Hu FC, Yu CY, Yang PC, Luh TY. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis. 2009;48:1526–33. Oxford: University of Chicago Press.PubMedCrossRefGoogle Scholar
  358. 358.
    Kim JW, Hattori A, Phongsamran PV. Drug-induced liver disease. Crit Care Nurs Clin. 2010;22:323–34. United States: Elsevier Inc.CrossRefGoogle Scholar
  359. 359.
    Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. 2011;66:1431–46. Oxford: Oxford University Press.PubMedPubMedCentralCrossRefGoogle Scholar
  360. 360.
    Terziroli Beretta-Piccoli B, Mieli-Vergani G, Bertoli R, Mazzucchelli L, Nofziger C, Paulmichl M, et al. Atovaquone/proguanil-induced autoimmune-like hepatitis. Hepatology. 2017;1:293–8. United States: John Wiley and Sons Inc.Google Scholar
  361. 361.
    Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Infectious DiseasesGeorgetown University Medical CenterWashington, DCUSA
  2. 2.Division of GastroenterologyGeorgetown University Medical CenterWashington, DCUSA

Personalised recommendations